Ociperlimab
Highest phase reached
Phase 3
Drug type
Antibody
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Antibody
- Drug name
- Ociperlimab
- bgb a1217
- Bgb-a1217
- BGB-A1217
- bgba 1217
- BGBA-1217
- bgba1217
- BGBA1217
- immunoglobulin g1 anti human receptor tigit human mus musculus monoclonal bgb a1217 gamma 1 chain disulfide with human mus musculus monoclonal bgb a1217 kappa chain dimer
- immunoglobulin g1 kappa anti homo sapiens tigit t cell immunoreceptor with ig domain and itim v set ig member 9 vsig9 v set and transmembrane member 3 vstm3 humanized monoclonal antibody gamma1 heavy chain humanized 1 449 vh homo sapiens ighv3 66 01 88 8 ighd ighj4 01 100 cdr imgt 8 8 12 26 33 51 58 97 108 1 119 homo sapiens ighg1 01 ng1m1 g1m17 ch1 k120 216 120 217 hinge 1 15 218 232 ch2 233 342 ch3 e12 358 m14 360 343 447 chs 448 449 120 449 222 214 disulfide with kappa light chain humanized 1 214 v kappa homo sapiens igkv3 15 01 87 4 igkj4 01 100 cdr imgt 6 3 9 27 32 50 52 89 97 1 107 homo sapiens igkc 01 100 km3 a45 1 153 v101 191 108 214 dimer 228 228 231 231 bisdisulfide produced in chinese hamster ovary cho cells glycoform alfa
- immunoglobulin g1 kappa anti homo sapiens tigit t cell immunoreceptor with ig domain and itim v set ig member 9 vsig9 v set and transmembrane member 3 vstm3 humanized monoclonal antibody ociperlimab
- IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS TIGIT (T-CELL IMMUNORECEPTOR WITH IG DOMAIN AND ITIM, V-SET IG MEMBER 9, VSIG9, V-SET AND TRANSMEMBRANE MEMBER 3, VSTM3)), HUMANIZED MONOCLONAL ANTIBODY (OCIPERLIMAB)
- IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS TIGIT (T-CELL IMMUNORECEPTOR WITH IG DOMAIN AND ITIM, V-SET IG MEMBER 9, VSIG9, V-SET AND TRANSMEMBRANE MEMBER 3, VSTM3)), HUMANIZED MONOCLONAL ANTIBODY; GAMMA1 HEAVY CHAIN HUMANIZED (1-449) (VH (HOMO SAPIENS IGHV3-66*01 (88.8%)-(IGHD)-IGHJ4*01 (100%)) CDR-IMGT (8.8.12) (26-33.51-58.97-108) (1-119)-HOMO SAPIENS IGHG1*01 NG1M1, G1M17 (CH1 K120 (216) (120-217), HINGE 1-15 (218-232), CH2 (233-342), CH3 E12 (358), M14 (360) (343-447), CHS (448-449)) (120-449)), (222-214')-DISULFIDE WITH KAPPA LIGHT CHAIN HUMANIZED (1'-214') (V-KAPPA (HOMO SAPIENS IGKV3-15*01 (87.4%)-IGKJ4*01 (100%)) CDR-IMGT (6.3.9) (27-32.50-52.89-97) (1'-107')-HOMO SAPIENS IGKC*01 (100%) KM3 A45.1 (153), V101 (191) (108'-214')); DIMER (228-228'':231-231'')-BISDISULFIDE, PRODUCED IN CHINESE HAMSTER OVARY (CHO) CELLS, GLYCOFORM ALFA
- IMMUNOGLOBULIN G1, ANTI-(HUMAN RECEPTOR TIGIT) (HUMAN-MUS MUSCULUS MONOCLONAL BGB-A1217 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL BGB-A1217 .KAPPA.-CHAIN, DIMER
- ociperlimab
- Ociperlimab
- ociperlimab [INN]
- OCIPERLIMAB [USAN]
- Ociperlimab [WHO-DD]
- ociperlimab inn
- ociperlimab usan
- ociperlimab who dd
- CAS registry numbers
- 2342597-93-5
- ChEMBL ID
- CHEMBL4650411
- FDA ingredient codes (UNII)
- 7JNY4KV3NK
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -mab
Mechanisms of action
- Mechanism
- T-cell immunoreceptor with Ig and ITIM domains inhibitor
- Action type
- Inhibitor
- Target
- T-cell immunoreceptor with Ig and ITIM domains
- Protein identifier
- Q495A1
Open Targets mechanisms
- Mechanism
- T-cell immunoreceptor with Ig and ITIM domains inhibitor
- Action type
- Inhibitor
- Target
- T-cell immunoreceptor with Ig and ITIM domains
- Condition
- Carcinoma, Hepatocellular
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000182
- Subject identifier
- D006528
- Condition
- Lymphoma, Large B-Cell, Diffuse
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000403
- Subject identifier
- D016403
- Condition
- Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Small Cell Lung Carcinoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000702
- Subject identifier
- D055752
- Condition
- Carcinoma, Non-Small-Cell Lung
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003060
- Subject identifier
- D002289
- Condition
- Esophageal Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0005922
- Subject identifier
- D004938
- Condition
- Uterine Cervical Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0002974
- Subject identifier
- D002583
- Condition
- Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0004992
- Subject identifier
- D009369
- Condition
- Breast Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0007254
- Subject identifier
- D001943
- Condition identifier
- EFO_0000616
- Highest recorded phase
- 1
- Condition identifier
- EFO_0003060
- Highest recorded phase
- 3
- Condition identifier
- EFO_0005922
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002974
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004992
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005070
- Condition identifier
- MONDO_0005233
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005580
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0007254
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0007256
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0008433
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0018905
- Highest recorded phase
- 1
- NCT04047862
- NCT04164199
- NCT04693234
- NCT04732494
- NCT04746924
- NCT04866017
- NCT05014815
- NCT05791097
- NCT04948697
- NCT04952597
- NCT05267054
- NCT05809895
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
- Component
- Heavy chain
- Type
- Protein
- Sequence
- EIVMTQSPATLSVSPGERATLSCKASQDVGTSVAWYQQKPGQAPRLLIYWITKGGGSTYYPDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARQTNYDFTMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
- Component
- Light chain
- Type
- Protein
- Sequence
- EIVMTQSPATLSVSPGERATLSCKASQDVGTSVAWYQQKPGQAPRLLIYWASARHTGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYSSYPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
- Component
- Glycosylation sites (N)
- Sequence
- 299 $ 299''''
- Component
- Disulfide bridges
- Sequence
- 22-96 $ 22''-96'' $ 23'-88' $ 23'''-88''' $ 134'-194' $ 134'''-194''' $ 146-202 $ 146''-202'' $ 214'-202 $ 214'''-202'' $ 228-228'' $ 231-231'' $ 263-323 $ 263''-323'' $ 369-427 $ 369''-427''
- Component
- Glycosylation sites (N)
- Sequence
- 299 $ 299''
Related records
Trials (13)
- A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC
- A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer
- A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer
- AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer
- Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
- Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer
- Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer
- Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer
- Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC.
- Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors
- Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer
- Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
- Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab
In development for (9)
- Breast cancer Phase 2
- Cancer Phase 3
- Cervical cancer Phase 2
- Diffuse large B-cell lymphoma Phase 1
- Esophageal squamous cell carcinoma Phase 2
- Hepatocellular carcinoma Phase 2
- Neoplasm Phase 3
- Non-small cell lung carcinoma Phase 3
- Small cell lung carcinoma Phase 2
Targets (1)
- TIGIT T-cell immunoreceptor with Ig and ITIM domains inhibitor